SAM
INO icon

Smartleaf Asset Management’s Inovio Pharmaceuticals INO Stock Holding History

Smartleaf Asset Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93 Hold
83
– – ﹤0.01% 3367
2026
Q1 		$139 Hold
83
– – ﹤0.01% 3370
2025
Q4 		$146 Buy
+83
New +$183 ﹤0.01% 3386

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Smartleaf Asset Management's INO Position: Q2 2026 in Review

Smartleaf Asset Management held its Inovio Pharmaceuticals (INO) position steady in Q2 2026 at 83 shares worth $93. The position accounts for ﹤0.01% of the portfolio, ranked #3367.

Smartleaf Asset Management first reported a position in INO in Q4 2025 and has held it in 3 quarters since. The position peaked at $146 in Q4 2025. 102 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • Smartleaf Asset Management held 83 shares of Inovio Pharmaceuticals worth $93 as of Q2 2026.
  • Smartleaf Asset Management left its Inovio Pharmaceuticals share count unchanged in Q2 2026.
  • Inovio Pharmaceuticals made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #3367 holding.
  • Smartleaf Asset Management first reported a position in Inovio Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Smartleaf Asset Management's Inovio Pharmaceuticals position peaked at $146 in Q4 2025.
  • 102 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.